Mayo Clinic Laboratory and Pathology Research Roundup: Jan. 29

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.


Featured Abstract

Pathways Impacted by Genomic Alterations in Pulmonary Carcinoid Tumors

Pulmonary carcinoid tumors account for up to 5% of all lung malignancies in adults, comprise 30% of all carcinoid malignancies, and are defined histologically as typical carcinoid and atypical carcinoid tumors. The role of specific genomic alterations in the pathogenesis of pulmonary carcinoid tumors remains poorly understood. Mayo Clinic researchers sought to identify genomic alterations and pathways that are deregulated in these tumors to find novel therapeutic targets for pulmonary carcinoid tumors. They performed integrated genomic analysis of carcinoid tumors comprising whole genome and exome sequencing, mRNA expression profiling, and SNP genotyping of specimens from normal lung, typical, and atypical carcinoid, and small cell lung carcinoma to fully represent the lung neuroendocrine tumor spectrum. The study identified mutated genes affecting cancer relevant pathways and biological processes that could provide opportunities for developing targeted therapies for pulmonary carcinoid tumors. The study was published in Clinical Cancer Research.


Published to PubMed This Week

kschrib

Kelley Schreiber

Kelley Schreiber is a Marketing Channel Manager at Mayo Medical Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her new kitten, and exploring new foods.